Innovating Works

BIOMEDCODE S.A.

Desconocido
INFRAPLUS: Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un HORIZON EUROPE HORIZON-INFRA-2023-DEV-01 In response to the HORIZON-INFRA-2023-DEV-01-03 call, INFRAPLUS aims to expand INFRAFRONTIER's capacity for human disease modelling, refine...
2024-06-20 - 2027-05-31 | Financiado
INFRAFRONTIER2020: Towards enduring mouse resources and services advancing research into human health and disease BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un H2020 H2020-INFRADEV-2016-2017 The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse...
2016-12-14 - 2021-12-31 | Financiado
BTCURE: BeTheCuRE BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP6 BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal model...
2011-04-01 - 2017-03-31 | Financiado
INFLA-CARE: Understanding inflammation associated tumorigenesis for the rational design of novel anti cancer the... BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7 Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cell...
Financiado
BTCURE: BeTheCuRE BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7 BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal model...
Financiado
MASTERSWITCH: Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7 Objective: To delineate the biological and molecular pathways that initiate and drive chronic inflammatory disease and to transform the know...
Financiado
ADDRESS: Joint training and research network on Chromatin Dynamics and the DNA Damage Response BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7 DNA is tightly wrapped around histones to form chromatin, a highly dynamic structure that can adopt different conformations with contrasting...
Financiado
CodeAge: The role of Chronic DNA damage in Ageing and Age related pathology BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7 Ageing is an inexorable homeostatic failure of largely unknown aetiology that leads to increased vulnerability to disease limiting the quali...
Financiado
TARKINAID: Targeting Src family tyrosine kinases in chronic autoimmune and inflammatory diseases BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7 The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.